Immucura
Immucura is dedicated to revolutionizing cancer treatment through innovative, non-invasive, and scientifically advanced therapies. The company focuses on personalized immunotherapy approaches, including dendritic cell therapy, nanothermia, biological terrain therapy, and cytokine-induced killer cell therapy, aiming to support the body's natural ability to fight cancer at its root. With a global presence and a team of experienced medical professionals, Immucura offers cutting-edge treatments and collaborates with partner clinics worldwide to improve patient outcomes and quality of life.
Industries
Nr. of Employees
small (1-50)
Products
Personalized integrative cancer therapy program (6 or 12 months)
Structured program combining autologous cellular immunotherapy, metabolic and nutritional interventions, supplementation and multidisciplinary follow-up over a 6- or 12-month period.
Personalized integrative cancer therapy program (6 or 12 months)
Structured program combining autologous cellular immunotherapy, metabolic and nutritional interventions, supplementation and multidisciplinary follow-up over a 6- or 12-month period.
Services
Telemedicine medical consultation and eligibility assessment
Remote consultation with a health coordinator or physician to assess patient eligibility and propose individualized therapy plans.
Personalized integrative cancer therapy program (6 or 12 months)
Structured multimodal program combining autologous cellular immunotherapy, metabolic and nutritional interventions, supplementation and multidisciplinary follow-up over a 6- or 12-month period.
Dendritic cell therapy service
Generation and administration of autologous dendritic cell vaccines using patient-derived material or defined antigen preparations with integrated immune monitoring and intradermal vaccination schedules.
NK-cell therapy and autologous NK expansion
Provision of activated and expanded autologous NK-cell infusion products produced using automated closed-system workflows for consolidation or therapeutic use.
DC–CIK combination cell therapy
Coordinated generation and delivery of dendritic cell and cytokine-induced killer cell combination immunotherapy alongside chemotherapy regimens with defined infusion schedules.
Integrative supportive services (blood analysis, nutrition, mental-health support)
Complementary diagnostics and supportive care including blood testing, nutritional counseling, supplementation planning and psychological support integrated into therapy programs.
Telemedicine medical consultation and eligibility assessment
Remote consultation with a health coordinator or physician to assess patient eligibility and propose individualized therapy plans.
Personalized integrative cancer therapy program (6 or 12 months)
Structured multimodal program combining autologous cellular immunotherapy, metabolic and nutritional interventions, supplementation and multidisciplinary follow-up over a 6- or 12-month period.
Dendritic cell therapy service
Generation and administration of autologous dendritic cell vaccines using patient-derived material or defined antigen preparations with integrated immune monitoring and intradermal vaccination schedules.
NK-cell therapy and autologous NK expansion
Provision of activated and expanded autologous NK-cell infusion products produced using automated closed-system workflows for consolidation or therapeutic use.
DC–CIK combination cell therapy
Coordinated generation and delivery of dendritic cell and cytokine-induced killer cell combination immunotherapy alongside chemotherapy regimens with defined infusion schedules.
Integrative supportive services (blood analysis, nutrition, mental-health support)
Complementary diagnostics and supportive care including blood testing, nutritional counseling, supplementation planning and psychological support integrated into therapy programs.
Expertise Areas
- Cellular immunotherapy
- Dendritic cell vaccine development
- Autologous cell therapy manufacturing
- Ex vivo NK and CIK cell expansion
Key Technologies
- Dendritic cell vaccines
- Leukapheresis and PBMC isolation
- Tumor lysate and peptide antigen loading
- Ex vivo NK cell activation and closed-system expansion